More on BHVN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.62 |
|
|||
| Open | $13.69 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $14.23 | ||||
| Day Low | $13.12 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 6,458,980 | ||||
- Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT
- Biohaven begins first human trial of brain-penetrant drug BHV-8100
- Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
- Form 8-K Biohaven Ltd. For: May 26
- Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
- Biohaven reports positive patient data for autoimmune disease drugs
- Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Dise
- Biohaven shares clinical data on epilepsy drug opakalim
- Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
- Form SCHEDULE 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
Entities mentioned with BHVN
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
